TariffCharts.com

Pharma 100% tariffs & metals restructuring take effect; IEEPA refund portal opens April 20

The April 2 proclamations marking Trump's most sweeping trade restructuring since taking office became fully operational this week. The metals tariff overhaul shifted from the previous byzantine metal-content calculations to clean full-value rates: 50% on primary metals, 25% on derivatives, and a temporary 15% cap on industrial equipment through 2027. The pharmaceutical tariff announcement simultaneously introduced a 100% baseline rate on patented drugs with a complex tier system offering preferential treatment to trade partners and companies with onshoring commitments. Both changes reflect lessons learned from 18 months of tariff implementation complexity.

The CAPE portal launch on April 20 represents the administration's most significant IEEPA refund operation to date, with CBS News reporting approximately 56,000 registered importers out of roughly 300,000 eligible - an 18.7% participation rate that aligns with court filing estimates of around 20%. The electronic ACH-only refund system and requirement for active CAPE Declaration filing create administrative hurdles that may explain the modest uptake rate. With the portal now operational, importers face a critical decision window as the two-year claim deadline approaches for many IEEPA-era payments.

Canada's April 8 publication of its second-year remission order through the Canada Gazette provides temporary relief for Canadian importers while maintaining pressure on the bilateral negotiating front. The order's extension from April 9, 2026 through April 8, 2027 ensures continuity but the two-year claim window creates urgency for businesses managing cross-border supply chains. The timing coincides with renewed trilogue negotiations in the EU, where Parliament's March 26 vote included suspension and sunrise clauses that could derail the framework agreement if US metals tariff concessions prove insufficient.

The Section 122 temporary tariff now faces a critical three-month window as its July 24 statutory expiration approaches simultaneously with potential CIT invalidation. The administration's race to complete Section 301 investigations on 76 countries before this dual deadline represents the most complex trade policy transition in decades. Success would create a permanent country-specific tariff architecture; failure could collapse the entire baseline 10% system and revert to a patchwork of Section 232 actions and bilateral deals. The pharmaceutical and metals restructuring may prove prescient if they provide operational frameworks that survive legal and statutory challenges to the broader tariff regime.

Section 122 at 10%, SCOTUS ruling in effect, Sec 232 tariffs unchanged, Section 301 probes underway but no outcomes yet.

Buying a Car